Purity CAS 34183 -22-7 Propafenone HCl Pharmaceutical Grade Propafenone HCl Antiarrhythmic Propafenone HCl

Propafenone is a broad-spectrum and highly effective membrane inhibitory antiarrhythmic drug with membrane stabilization and competitiveness β Receptor blocking effect. It can reduce myocardial excitability, prolong action potential duration and effective refractory period, and prolong conduction. Clinically, it can be used to prevent and treat ventricular and supraventricular ectopic beats, ventricular or supraventricular tachycardia, preexcitation syndrome, and ventricular fibrillation after electroconversion. It has the characteristics of fast onset and long-lasting effect.

It is a sodium channel blocker with a rapid anti arrhythmic effect. Directly stabilize the cell membrane, reduce the maximum rate of rise of action potential phase 0 of myocardial conduction fibers and myocardial cells, slow down the conduction, prolong the time course of action potential and effective refractory period, and extend or block the forward and reverse conduction of bypass. Raise the myocardial excitation threshold, reduce the spontaneous excitability of myocardial cells, block the reentry pathway, and eliminate reentry excitation. There is also a mild inhibition of myocardial contraction and a local anesthetic effect similar to that of procaine.
Oral administration is suitable for ventricular premature beats and paroxysmal ventricular tachycardia. Secondly, there are supraventricular arrhythmias, including atrial premature beats, paroxysmal supraventricular tachycardia, and preexcitation syndrome with supraventricular tachycardia, atrial flutter, or atrial fibrillation, but the effectiveness of correcting atrial fibrillation or atrial flutter is poor.
Intravenous injection is suitable for paroxysmal ventricular tachycardia and supraventricular tachycardia (including those with preexcitation syndrome). Oral administration is suitable for atrial and ventricular premature beats to prevent the onset of supraventricular tachycardia. The effect of cardioversion on atrial fibrillation and atrial flutter is poor. Intravenous injection is suitable for stopping paroxysmal supraventricular tachycardia, ventricular tachycardia episodes, and episodes of preexcitation syndrome with supraventricular tachycardia, and slowing down the ventricular rate of atrial fibrillation or atrial flutter. This product is mainly used for preexcitation syndrome with supraventricular arrhythmias and reentrant supraventricular tachycardia through the atrioventricular node.